Key Takeaways
- • Techcyte closed a $15 million Series funding round led by Van Tuyl Companies, with participation from existing investors Zoetis Inc. and Mayo Clinic, positioning the company to accelerate AI-powered diagnostic solutions in pathology.
- • The company specializes in AI-driven digital diagnostics for anatomic and clinical pathology, addressing a critical segment within clinical laboratory automation and diagnostic imaging.
- • Existing institutional investors—including veterinary health platform Zoetis and Mayo Clinic—retained positions, signaling continued confidence in the company's technology and market trajectory.
- • The funding round supports Techcyte's expansion in a healthcare sector increasingly focused on automation, accuracy, and operational efficiency in pathology workflows.
Summary
Techcyte, a developer of artificial intelligence-powered digital diagnostics for anatomic and clinical pathology, announced the completion of a $15 million capital raise on May 1, 2026. Van Tuyl Companies led the funding round, with additional participation from the company's existing investor base: Zoetis Inc., a global leader in animal health, and Mayo Clinic, the Minnesota-based healthcare and research institution.
The Orem, Utah-based company operates at the intersection of clinical diagnostics and artificial intelligence, serving the pathology market with digital diagnostic solutions designed to enhance accuracy and efficiency in anatomic and clinical laboratory settings. The capital infusion reflects sustained investor confidence in both the company's technology and the broader market opportunity in AI-enabled healthcare diagnostics.
The composition of the funding syndicate underscores the strategic value of Techcyte's platform. Zoetis's participation reflects potential applications within veterinary pathology, while Mayo Clinic's continued involvement suggests ongoing clinical validation and integration opportunities within a leading healthcare system. Van Tuyl Companies' lead role in the round indicates institutional backing from an established investor with healthcare and technology sector experience.
This funding round positions Techcyte to accelerate product development, market expansion, and commercialization efforts in a healthcare environment increasingly characterized by demand for diagnostic automation, operational efficiency, and AI-assisted clinical decision-making in pathology workflows.
The Orem, Utah-based company operates at the intersection of clinical diagnostics and artificial intelligence, serving the pathology market with digital diagnostic solutions designed to enhance accuracy and efficiency in anatomic and clinical laboratory settings. The capital infusion reflects sustained investor confidence in both the company's technology and the broader market opportunity in AI-enabled healthcare diagnostics.
The composition of the funding syndicate underscores the strategic value of Techcyte's platform. Zoetis's participation reflects potential applications within veterinary pathology, while Mayo Clinic's continued involvement suggests ongoing clinical validation and integration opportunities within a leading healthcare system. Van Tuyl Companies' lead role in the round indicates institutional backing from an established investor with healthcare and technology sector experience.
This funding round positions Techcyte to accelerate product development, market expansion, and commercialization efforts in a healthcare environment increasingly characterized by demand for diagnostic automation, operational efficiency, and AI-assisted clinical decision-making in pathology workflows.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.